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Cervical cancer remains an important cause of 
morbidity and mortality in South Africa (SA).[1] The 
age-standardised incidence rate of cervical cancer in 
southern Africa is approximately 27/100  000,[2] and 
most cases are diagnosed in late stages. Persistent 
infection with oncogenic human papillomavirus (HPV) is an 
essential step in the development of invasive cervical cancer.[3] HPV 
is highly infectious, but does not cause disease in all cases, and most 
individuals will clear infections. Since HPV is almost exclusively an 
epithelial disease, most transient HPV infections do not confer long-
term immunity owing to a poor immune response.
A national cervical cancer prevention programme was launched 
in SA in 2000, offering three Papanicolaou smears in a woman’s 
lifetime, starting after the age of 30 at 10-year intervals, but has had 
limited success in reducing the incidence of HPV-associated disease. 
Some provinces in SA have fairly well-developed cytology screening 
services, but there is poor uptake of prevention services for cancer. 
Among women with abnormal cytology, there is also significant loss 
to follow-up after the initial screening test.[4]
Since the introduction of effective HPV vaccines, a primary 
preventive strategy became available to combat the epidemic. 
Currently there are two vaccines registered in SA: the bivalent 
vaccine Cervarix, containing virus-like particles (VLPs) for HPV 
types 16 and 18, and the quadrivalent vaccine Gardasil, containing 
VLP antigens for HPV types 16 and 18 as well as non-oncogenic 
HPV types 6 and 11. VLPs are combined with an adjuvant, which 
leads to an improved immune response and long-term efficacy. 
Both vaccines have been extensively tested in large populations, 
and have also been found to be safe and immunogenic among 
African populations.[5] The bivalent HPV vaccine has also shown 
sustained immune responses in HIV-positive women, and was 
well tolerated.[6] Local reactions such as pain, swelling and redness 
can occur, as may systemic adverse events including fever, nausea, 
dizziness, fatigue, headache and myalgia.
Cost-effectiveness studies have shown universal, female-
only HPV vaccination before exposure to be an effective and 
economically viable option in developed countries.[7] Recently 
there has been increasing emphasis on the inclusion of low- and 
middle-income countries in the drive to reduce the global cancer 
burden. Evidence from qualitative studies suggests that South 
Africans will support introduction of HPV vaccination, but that 
education remains a key ingredient in any roll-out.[8] Adolescent 
health was identified as an area for development in the SA 
National Health Initiative Green Paper, with preventive health an 
important part of this plan. This focus is linked to a re-engineered 
primary healthcare plan and a newly developed school health 
programme (SHP).
In May 2013, Dr Aaron Motsoaledi, national Minister of Health, 
announced during the health budget speech that: ‘... we shall 
commence to administer the HPV vaccines as part of our SHP ...’. 
This courageous step is widely applauded in view of an uncontrolled 
cervical cancer epidemic resulting from high prevalence rates of HPV 
and HIV and the relatively unsuccessful cervical cancer screening 
programme described above. The success of this programme will 
depend on offering the vaccine to the target group via a functional 
SHP, education, and high vaccine uptake and completion rates. Data 
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on factors influencing successful school-
based implementation as well as acceptance 
rates among SA primary schoolgirls and 
their parents are limited.
This paper describes recruitment, 
information provided and consent and 
assent methods used, and reports on the 
acceptance of HPV vaccination and 
completion rates among learners invited 




Approval to conduct the project in 
schools was obtained from the national 
and provincial departments of health and 
education. Ethics approval was received 
from the participating university human 
research ethics committees (Stellenbosch 
N11/01/008 and Pretoria 219/2009). There 
was discussion between the investigators and 
school principals, important teachers and 
the school governing bodies to explain the 
rationale of the work.
Study procedures
Selection of sites and participants
Primary schools in low socioeconomic areas 
in Western Cape and Gauteng provinces 
were identified and contacted to invite 
them to participate in this prospective 
demonstration study. Children in grades 
4 - 7 received an invitation letter to an 
information evening to take home.
Information, consent and assent procedures
Teachers encouraged learners to bring the 
reply slip back. An information event was 
scheduled at each school in the afternoon 
or early evening. At the information 
events parents were interviewed after 
informed consent for the interview had 
been obtained. Structured interviews were 
conducted by trained interviewers and 
lasted about 20 minutes. The interview 
focused on demographic information and 
knowledge and perceptions of cervical 
cancer screening and vaccination. After 
the interviews, information about cervical 
cancer and ways of preventing it, including 
vaccination and screening, was given to 
parents and learners. The parents were then 
given the opportunity to provide written 
consent for vaccination of their children. 
Children were asked to give written assent 
as well, in order to meet research ethics 
requirements. Children aged 12 years and 
older were legally capable of giving consent 
without parental consent. The parents 
were invited to take part in a screening 
programme.
Parents who did not attend information 
events were given the opportunity to give 
consent after written information leaflets 
were sent home with their children. These 
consent forms were collected by teachers 
before the vaccination date.
Vaccine procedures
Vaccines for the study were donated by both 
vaccine companies. For practical reasons, 
the majority of girls in a particular school 
received the same brand of vaccine. All 
children younger than 10 years received 
Gardasil, owing to licensing at the time of 
the study. Vaccination was performed and 
recorded by registered nurses during school 
hours.
Schools were visited on at least two 
occasions for each vaccination time point 
to account for absenteeism. Learners were 
observed for 20 minutes after each dose for 
possible early adverse events.
Statistical analysis
For the purposes of this analysis, we defined 
the invited cohort (IC) as all female learners, 
aged 9 years and older, enrolled in grades 4, 
5, 6 and 7. The consented cohort (CC) was 
defined as all participants who had written 
parental consent as well as assent from the 
learner herself. Girls with consent who did 
not receive the vaccine were included in the 
CC. The vaccinated cohort (VC) included 
all girls who received at least one dose of 
vaccine.
Consent rate was calculated as the CC as 
a proportion of the IC. Vaccine uptake rates 
were calculated[9] in a number of ways to 
allow comparison with previously published 
HPV vaccine reports. The consented uptake 
rate was calculated as the VC as a proportion 
of the CC, and the invited uptake rate was 
calculated as the VC as a proportion of the IC.
Vaccine completion was calculated using 
the VC as denominator, while sufficient 
vaccination was calculated using the IC 
as denominator. When two vaccine doses 
were administered, data for girls receiving 
the two doses within a short period of 
time (<6 months apart) were separated 
from those who received the vaccines at 
least 6 months apart. For the purposes 
of these calculations, girls who received 
at least two doses 6 months apart were 
considered sufficiently vaccinated, while 
those receiving no dose at 6 months were 
considered insufficiently vaccinated. This is 
based on recent data suggesting protective 
antibody levels against vaccine HPV types 
in similar recipients.[10]
Results
The number of girls of the target age enrolled 
in the schools approached was 3 465. A total 
of 2 046 girls had written parental consent as 
well as written child assent, and 2 030 girls 
received at least one dose. These cohorts, 
shown in Table 1, were used to calculate 
vaccination success rates.
The rate of consent for the total study 
population was 59.0%. We were able to 
confirm the consent documents of 87.5% 
of all parents who attended the information 
events in Gauteng. Similar data for the 
Western Cape were not available. Of the 
consented children, almost all (99.2%) 
received at least one dose of vaccine. When 
vaccine uptake rates were calculated for the 
total target population, we obtained rates of 
63.7% for the Gauteng schools and 53.9% in 
the Western Cape. Recruitment documents 
and methods were identical for the two 
provinces, and the reasons for the observed 
difference in the rate of vaccine uptake were 
probably independent of the study method. 
These figures are set out in Table 2.
Table 1. Study population and cohorts
Gauteng girls (n) Western Cape girls (n) Total girls (N)
IC 1 654 1 811 3 465
CC 1 059 987 2 046
VC 1 053 977 2 030
IC = invited cohort; CC = consented cohort; VC = vaccinated cohort.
Table 2. Vaccine consent and uptake rates
Gauteng girls Western Cape girls Total girls
Consent rate, n/N (%) 1 059/1 654 (64.0) 987/1 811 (54.5) 2 046/3 465 (59.0)
Consented uptake rate, 
n/N (%)
1 053/1 059 (99.4) 977/987 (99.0) 2 030/2 046 (99.2)
Invited uptake rate, n/N (%) 1 053/1 654 (63.7) 977/1 811 (53.9) 2 030/3 465 (58.6)
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Regarding vaccine completion rates, in 
the Western Cape 93.3% of all girls who 
started vaccination received all three doses, 
and in Gauteng this figure was 82.6%. This 
difference in completion rates is attributed 
in part to two schools in Gauteng where the 
third vaccine dose was scheduled for the 
following calendar year. In the total group, 
91.6% of vaccinated girls were considered 
sufficiently vaccinated, the figure again being 
higher in the Western Cape than in Gauteng. 
Completion rates are set out in Table 3.
Considering both the influences of vaccine 
uptake and doses received, 53.7% of the target 
population in this study was considered 
sufficiently vaccinated at the end of the study 
period. Another 4.9% were vaccinated, but 
received a suboptimal vaccine dosage – 
usually the first two doses not followed by 
a third dose 6 months after the first dose. 
Detailed data are presented in Table 4.
Vaccination proceeded without any 
serious side-effects, and no serious adverse 
events were reported. There was protocol 
violation in two instances where two girls 
received one dose each without full written 
consent.
Discussion
In general, the staff at the schools 
co-operated and supported the study. At the 
majority of schools, staff members helped 
with the information evenings. Attendance 
at these meetings varied from school to 
school and according to seasons, television 
schedules and safety concerns. Most of 
the parents who attended the information 
events gave consent for vaccination of their 
children, but a significant percentage did 
not attend these events and did not reply 
to the written invitation to take part in the 
study. The successful Australian school-
based programme sends information to 
parents and asks for a detailed consent form 
to be returned to the school.[11] Information 
leaflets were also used to communicate 
with parents in a demonstration project 
in another province of SA, but the authors 
do not mention the number of children 
approached or the proportion for whom 
parental consent was achieved.[12]
Information leaflets may work in certain 
schools, but our experience was that about 
30 - 40% of parents did not respond to 
letters sent home with the learners. In 
the current study, relatively limited written 
information was provided to parents, but 
written information was combined with an 
invitation to an information event at which 
detailed verbal information was given and 
opportunity for questions and discussion 
provided. Using this recruitment method, 
a consent rate of almost 90% was reached 
among parents attending the information 
event, v. a rate of almost 60% for the total 
IC.
The high acceptance rate following better 
information underlines the importance of 
clear, direct communication with parents. 
In Rwanda a high rate of acceptance was 
achieved after educational interventions to 
parents.[13] There seems to be a better response 
to vaccination uptake in certain populations 
when interactive communication (rather 
than written only) strategies are used for 
transfer of information.[14] Verbal, interactive 
information sessions may be key to success 
in areas where literacy levels are low.
Uptake rates in many HPV vaccination 
projects around the world have been 
reported as high.[11,12] In our CC, 99.4% of 
girls were vaccinated and 91.6% received 
at least two doses of vaccine 6 months 
apart. Another 7.5% received their second 
dose after the first without receiving the 
last, while 87.8% received all three doses. 
Lower uptake was achieved when all invited 
girls are considered, but this is difficult to 
compare with other studies owing to a lack 
of local data.[12]
Linking primary and secondary prevention 
in a mother-daughter programme was tested 
in this study and other sites.[12,15] Mothers 
and/or caregivers of learners were given 
the opportunity to undergo screening. The 
results of this part of the study will be 
reported in the next issue of the SAMJ.[9]
Conclusion
This implementation project demonstrated that 
HPV vaccination is practical and safe in SA 
schools. Political and community acceptance 
is good, and we encountered positive attitudes 
towards vaccination. This study mimicked a 
governmental vaccine roll-out programme, 
and despite several challenges, high completion 
rates were achieved.
Parents who received complete information 
on the HPV vaccine demonstrated a very 
high acceptance rate, appropriate information 
contributing significantly to vaccine uptake. 
This effective communication is shown to 
achieve better coverage for vaccination; 
importantly, the awareness created may also 
lead to improved screening uptake. Vaccine 
completion was much improved by ensuring 
administration of all doses within a single 
calendar or academic year.
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Table 3. Completion rates in the VC (N=2 030)
Gauteng, n (%) Western Cape, n (%) Total, n (%)
Three doses received 870 (82.6) 912 (93.3) 1 782 (87.8)
Two doses 6 months apart 71 (6.7) 6 (0.6) 77 (3.8)
Sufficiently vaccinated 941 (89.4) 918 (94.0) 1 859 (91.6)
Single dose received 9 (0.9) 10 (1.0) 19 (0.9)
Two doses <6 months apart 103 (9.8) 49 (5.0) 152 (7.5)
Insufficiently vaccinated 112 (10.6) 59 (6.0) 171 (8.4)
Total VC 1 053 (100) 977 (100) 2 030 (100)
VC = vaccinated cohort.
Table 4. Vaccination rates in the IC (N=3 465)
Gauteng, n (%) Western Cape, n (%) Total, n (%)
Three doses received 870 (52.6) 912 (50.4) 1 782 (51.4)
Two doses 6 months apart 71 (4.3) 6 (0.3) 77 (2.2)
Sufficiently vaccinated 941 (56.9) 918 (50.7) 1 859 (53.7)
Single dose received 9 (0.5) 10 (0.6) 19 (0.5)
Two doses <6 months apart 103 (6.2) 49 (2.7) 152 (4.4)
No vaccine received 601 (36.3) 834 (46.1) 1 435 (41.4)
Insufficiently vaccinated 713 (43.1) 893 (49.3) 1 606 (46.3)
Total IC 1 654 (100) 1 811 (100) 3 465 (100)
IC = invited cohort.
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